SG10202100683RA - Monoclonal antibody against melk and utilization thereof - Google Patents
Monoclonal antibody against melk and utilization thereofInfo
- Publication number
- SG10202100683RA SG10202100683RA SG10202100683RA SG10202100683RA SG10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA SG 10202100683R A SG10202100683R A SG 10202100683RA
- Authority
- SG
- Singapore
- Prior art keywords
- utilization
- monoclonal antibody
- antibody against
- against melk
- melk
- Prior art date
Links
- 101150054634 melk gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016169085 | 2016-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202100683RA true SG10202100683RA (en) | 2021-03-30 |
Family
ID=61301839
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901435UA SG11201901435UA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
SG10202100683RA SG10202100683RA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901435UA SG11201901435UA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US11066477B2 (en) |
EP (1) | EP3508576A4 (en) |
JP (1) | JP7094557B2 (en) |
KR (1) | KR102579047B1 (en) |
CN (1) | CN109890963B (en) |
AU (1) | AU2017318907B2 (en) |
BR (1) | BR112019003408A2 (en) |
CA (1) | CA3035160A1 (en) |
IL (1) | IL264826B1 (en) |
MX (1) | MX2019002269A (en) |
RU (1) | RU2756982C2 (en) |
SG (2) | SG11201901435UA (en) |
TW (1) | TWI780067B (en) |
WO (1) | WO2018043311A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3973000A4 (en) * | 2019-06-07 | 2023-09-06 | Adimab, LLC | High affinity anti-cd3 antibodies, and methods for their generation and use |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
JP5087059B2 (en) | 2001-10-31 | 2012-11-28 | 杏林製薬株式会社 | Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
CA2535808A1 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Melks as modifiers of the rac pathway and methods of use |
JP4721903B2 (en) | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | Novel tumor antigen protein and use thereof |
WO2006016525A2 (en) | 2004-08-10 | 2006-02-16 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
JP2009502115A (en) | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | Diagnostic method for small cell lung cancer |
WO2007058933A2 (en) | 2005-11-10 | 2007-05-24 | Exelixis, Inc. | Melks as modifiers of the rho pathway and methods of use |
WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
WO2009131365A2 (en) * | 2008-04-21 | 2009-10-29 | 한국생명공학연구원 | Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer |
TWI466680B (en) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Melk epitope peptides and vaccines containing the same |
TWI485245B (en) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | Modified melk peptides and vaccines containing the same |
WO2012016082A1 (en) | 2010-07-30 | 2012-02-02 | Oncotherapy Science, Inc. | Quinoline derivatives and melk inhibitors containing the same |
EP2574929A1 (en) | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker in diagnosing prostate cancer (PC) |
TWI623536B (en) | 2012-01-19 | 2018-05-11 | 腫瘤療法 科學股份有限公司 | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
RU2504785C1 (en) | 2012-11-23 | 2014-01-20 | Общество с ограниченной ответственностью "Синтавр" | Diagnostic technique for breast cancer |
CN104995208A (en) * | 2013-01-11 | 2015-10-21 | 诺华股份有限公司 | MELK regulation for the treatment of breast cancer |
CN108064284A (en) | 2014-12-12 | 2018-05-22 | 国立大学法人京都大学 | The extremely antibody of the corner structure of 22 and 23 of specific recognition amyloid beta |
-
2017
- 2017-08-25 BR BR112019003408A patent/BR112019003408A2/en unknown
- 2017-08-25 WO PCT/JP2017/030443 patent/WO2018043311A1/en unknown
- 2017-08-25 RU RU2019107355A patent/RU2756982C2/en active
- 2017-08-25 CA CA3035160A patent/CA3035160A1/en active Pending
- 2017-08-25 AU AU2017318907A patent/AU2017318907B2/en active Active
- 2017-08-25 EP EP17846316.2A patent/EP3508576A4/en active Pending
- 2017-08-25 SG SG11201901435UA patent/SG11201901435UA/en unknown
- 2017-08-25 JP JP2018537214A patent/JP7094557B2/en active Active
- 2017-08-25 CN CN201780067183.0A patent/CN109890963B/en active Active
- 2017-08-25 SG SG10202100683RA patent/SG10202100683RA/en unknown
- 2017-08-25 IL IL264826A patent/IL264826B1/en unknown
- 2017-08-25 US US16/328,259 patent/US11066477B2/en active Active
- 2017-08-25 KR KR1020197009204A patent/KR102579047B1/en active IP Right Grant
- 2017-08-25 MX MX2019002269A patent/MX2019002269A/en unknown
- 2017-08-28 TW TW106129146A patent/TWI780067B/en active
Also Published As
Publication number | Publication date |
---|---|
RU2019107355A3 (en) | 2020-11-02 |
IL264826A (en) | 2019-04-30 |
EP3508576A4 (en) | 2020-04-22 |
US11066477B2 (en) | 2021-07-20 |
TWI780067B (en) | 2022-10-11 |
RU2019107355A (en) | 2020-10-01 |
AU2017318907B2 (en) | 2023-07-06 |
BR112019003408A2 (en) | 2019-06-25 |
CN109890963A (en) | 2019-06-14 |
MX2019002269A (en) | 2019-09-18 |
KR20190043591A (en) | 2019-04-26 |
JP7094557B2 (en) | 2022-07-04 |
TW201818972A (en) | 2018-06-01 |
JPWO2018043311A1 (en) | 2019-06-24 |
CA3035160A1 (en) | 2018-03-08 |
KR102579047B1 (en) | 2023-09-14 |
AU2017318907A1 (en) | 2019-03-21 |
SG11201901435UA (en) | 2019-03-28 |
AU2017318907A2 (en) | 2019-03-28 |
IL264826B1 (en) | 2024-02-01 |
EP3508576A1 (en) | 2019-07-10 |
CN109890963B (en) | 2023-10-03 |
RU2756982C2 (en) | 2021-10-07 |
US20190185575A1 (en) | 2019-06-20 |
WO2018043311A1 (en) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290412B (en) | Novel cd47 monoclonal antibodies and uses thereof | |
HK1259426A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
HK1255604A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
IL264011A (en) | Antibodies against tim3 and uses thereof | |
IL268206A (en) | Bcma-targeting antibody and use thereof | |
ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
IL262092B (en) | Humanized anti-pacap antibodies and uses thereof | |
HK1251587A1 (en) | Antibody against glypican-3 and application thereof | |
IL273411A (en) | Anti-pd-l1 antibody and uses thereof | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
ZA202000113B (en) | Anti-ctla-4 antibodies and uses thereof | |
ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
HK1246805A1 (en) | Broad-spectrum monoclonal anti-flu b antibody and uses thereof | |
IL263242A (en) | Cytosol-penetrating antibody and use thereof | |
IL258924A (en) | Humanized anti-dkk2 antibody and uses thereof | |
IL274502A (en) | Anti-ox40 antibodies and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
SG11202003585VA (en) | Anti-vista antibody and use thereof |